Michael Fluck

2.3k total citations
24 papers, 770 citations indexed

About

Michael Fluck is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Michael Fluck has authored 24 papers receiving a total of 770 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Immunology. Recurrent topics in Michael Fluck's work include Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (11 papers) and Melanoma and MAPK Pathways (7 papers). Michael Fluck is often cited by papers focused on Cancer Immunotherapy and Biomarkers (11 papers), Immunotherapy and Immune Responses (11 papers) and Melanoma and MAPK Pathways (7 papers). Michael Fluck collaborates with scholars based in Germany, United States and Spain. Michael Fluck's co-authors include Lisa Zimmer, Axel Hauschild, Dirk Schadendorf, Claus Garbe, Thomas Eigentler, Peter Mohr, Arndt Vogel, Jan Leipe, Matthias Pauschinger and Jessica C. Hassel and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

Michael Fluck

22 papers receiving 754 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael Fluck Germany	11	501	379	223	186	173	24	770
Virginia Picasso Italy	12	400 0.8×	314 0.8×	197 0.9×	157 0.8×	101 0.6×	16	661
Christine Longvert France	12	353 0.7×	233 0.6×	106 0.5×	43 0.2×	59 0.3×	34	525
Florentia Dimitriou Switzerland	16	665 1.3×	250 0.7×	230 1.0×	27 0.1×	150 0.9×	50	936
Heather M. Shaw United Kingdom	13	352 0.7×	349 0.9×	93 0.4×	17 0.1×	132 0.8×	34	725
Darab Kamanabrou Germany	6	372 0.7×	305 0.8×	139 0.6×	14 0.1×	81 0.5×	7	517
Janice Shipe-Spotloe United States	9	368 0.7×	245 0.6×	259 1.2×	30 0.2×	24 0.1×	16	547
M. Thomas France	8	758 1.5×	503 1.3×	238 1.1×	9 0.0×	172 1.0×	20	1.1k
Razi Ghori United States	13	763 1.5×	400 1.1×	234 1.0×	12 0.1×	167 1.0×	27	953
Ruediger Rueger Switzerland	9	422 0.8×	500 1.3×	33 0.1×	20 0.1×	215 1.2×	12	769
Nyam Kamsu-Kom France	10	615 1.2×	662 1.7×	101 0.5×	9 0.0×	117 0.7×	12	1.0k

Countries citing papers authored by Michael Fluck

Since Specialization

Citations

This map shows the geographic impact of Michael Fluck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Fluck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Fluck more than expected).

Fields of papers citing papers by Michael Fluck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Fluck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Fluck. The network helps show where Michael Fluck may publish in the future.

Co-authorship network of co-authors of Michael Fluck

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Fluck. A scholar is included among the top collaborators of Michael Fluck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Fluck. Michael Fluck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Becker, Jürgen C., Anja Gesierich, Ulrike Leiter, et al.. (2025). Avelumab plus cetuximab in patients with unresectable stage III or IV cutaneous squamous cell carcinoma: clinical activity and safety results from AliCe, a single-arm multicentre phase II DeCOG trial. British Journal of Dermatology. 193(5). 865–875.

Becker, Jürgen C., Bastian Schilling, Lisa Zimmer, et al.. (2023). 1087MO A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study. Annals of Oncology. 34. S654–S655. 3 indexed citations

Eigentler, Thomas, Lucie Heinzerling, Juergen Krauss, et al.. (2021). 1010P Intratumorally administered CV8102 in patients with advanced solid tumors: Preliminary results from completed dose escalation in study 008. Annals of Oncology. 32. S853–S853. 3 indexed citations

Eigentler, Thomas, Franz Bauernfeind, Jürgen C. Becker, et al.. (2020). A phase I dose-escalation and expansion study of intratumoral CV8102 as single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors.. Journal of Clinical Oncology. 38(15_suppl). 3096–3096. 11 indexed citations

Eigentler, Thomas, Michael Fluck, Jessica C. Hassel, et al.. (2019). Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open. 4(3). e000491–e000491. 157 indexed citations

Schadendorf, Dirk, Jessica C. Hassel, Michael Fluck, et al.. (2019). Adjuvant immunotherapy with nivolumab (NIVO) alone or in combination with ipilimumab (IPI) versus placebo in stage IV melanoma patients with no evidence of disease (NED): A randomized, double-blind phase II trial (IMMUNED). Annals of Oncology. 30. v903–v904. 6 indexed citations

Mihailovic, Nataša, et al.. (2019). Vogt-Koyanagi-Harada-artige Uveitis unter Immun-Checkpoint-Inhibitor-Therapie beim metastasierten malignen Melanom. Der Ophthalmologe. 117(5). 467–471. 16 indexed citations

Tietze, Julia K., Andrea Forschner, Carmen Loquai, et al.. (2018). The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study. Oncotarget. 9(76). 34336–34346. 24 indexed citations

McArthur, Grant A., Michele Maio, Ana Arance, et al.. (2016). Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. Annals of Oncology. 28(3). 634–641. 168 indexed citations

10.

Huebner, Jutta, Peter Mohr, Jan‐Christoph Simon, et al.. (2016). Use of complementary medicine in metastatic melanoma patients treated with ipilimumab within a clinical trial. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 14(5). 508–513. 6 indexed citations

11.

Zimmer, Lisa, Julia Vaübel, Peter Mohr, et al.. (2015). Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma. PLoS ONE. 10(3). e0118564–e0118564. 181 indexed citations

12.

Zimmer, Lisa, Thomas Eigentler, Felix Kiecker, et al.. (2015). Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma. Journal of Translational Medicine. 13(1). 351–351. 51 indexed citations

13.

Kuhlmann, Jan Dominik, et al.. (2015). Increased level of circulating U2 small nuclear RNA fragments indicates metastasis in melanoma patients. Clinical Chemistry and Laboratory Medicine (CCLM). 53(4). 605–11. 16 indexed citations

14.

Zimmer, Lisa, Thomas Eigentler, Peter Mohr, et al.. (2014). Open-label, multicenter, single-arm phase II study (DeCOG-Trial) to further evaluate the efficacy and safety of ipilimumab in patients with cutaneous melanoma and rare subgroups.. Journal of Clinical Oncology. 32(15_suppl). 9031–9031. 8 indexed citations

15.

Hauschild, Axel, Katharina C. Kähler, Martin Schäfer, & Michael Fluck. (2008). Interdisciplinary management recommendations for toxicity associated with interferon‐alfa therapy. JDDG Journal der Deutschen Dermatologischen Gesellschaft. 6(10). 829–837. 11 indexed citations

16.

Atzpodien, Jens, et al.. (2007). Cisplatin, gemcitabine and treosulfan is effective in chemotherapy-pretreated relapsed stage IV uveal melanoma patients. Cancer Chemotherapy and Pharmacology. 62(4). 685–688. 12 indexed citations

17.

Atzpodien, Jens, et al.. (2007). Cisplatin, gemcitabine, and treosulfan in relapsed stage IV cutaneous malignant melanoma patients. British Journal of Cancer. 97(10). 1329–1332. 4 indexed citations

18.

Fluck, Michael, Darab Kamanabrou, Andrea Lippold, Martina Reitz, & Jens Atzpodien. (2005). Dose-Dependent Treatment Benefit in High-Risk Melanoma Patients Receiving Adjuvant High-Dose Interferon Alfa-2b. Cancer Biotherapy and Radiopharmaceuticals. 20(3). 280–289. 2 indexed citations

19.

Letsch, Anne, Ulrich Keilholz, Michael Fluck, et al.. (2005). Peptide vaccination after repeated resection of metastases can induce a prolonged relapse‐free interval in melanoma patients. International Journal of Cancer. 114(6). 936–941. 10 indexed citations

20.

Atzpodien, Jens, Michael Fluck, & Martina Reitz. (2004). Individualized Synthetic Peptide Vaccines with GM-CSF in Locally Advanced Melanoma Patients. Cancer Biotherapy and Radiopharmaceuticals. 19(6). 758–763. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact